Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Short Interest Down 33.8% in April

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) saw a large decrease in short interest in April. As of April 30th, there was short interest totaling 28,393,792 shares, a decrease of 33.8% from the April 15th total of 42,883,635 shares. Currently, 7.1% of the shares of the company are sold short. Based on an average daily trading volume, of 13,050,501 shares, the days-to-cover ratio is presently 2.2 days.

Analyst Ratings Changes

A number of analysts recently commented on SGMO shares. Zacks Research cut shares of Sangamo Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Thursday, April 16th. Wall Street Zen downgraded shares of Sangamo Therapeutics to a “strong sell” rating in a report on Saturday, January 31st. Weiss Ratings reissued a “sell (e+)” rating on shares of Sangamo Therapeutics in a report on Thursday, January 22nd. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Sangamo Therapeutics in a report on Tuesday, February 10th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Reduce” and a consensus price target of $5.50.

Insider Activity at Sangamo Therapeutics

In related news, SVP Nathalie Dubois-Stringfellow sold 345,942 shares of the company’s stock in a transaction that occurred on Tuesday, April 21st. The shares were sold at an average price of $0.26, for a total transaction of $89,944.92. Following the sale, the senior vice president directly owned 332,769 shares in the company, valued at approximately $86,519.94. This represents a 50.97% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 4.10% of the company’s stock.

Hedge Funds Weigh In On Sangamo Therapeutics

A number of large investors have recently added to or reduced their stakes in SGMO. GSA Capital Partners LLP boosted its stake in shares of Sangamo Therapeutics by 63.1% during the third quarter. GSA Capital Partners LLP now owns 3,662,478 shares of the biopharmaceutical company’s stock valued at $2,466,000 after purchasing an additional 1,417,029 shares during the period. Oracle Investment Management Inc. purchased a new position in shares of Sangamo Therapeutics in the third quarter worth $677,000. Prelude Capital Management LLC purchased a new position in shares of Sangamo Therapeutics in the third quarter worth $67,000. Boothbay Fund Management LLC increased its position in shares of Sangamo Therapeutics by 10.8% in the third quarter. Boothbay Fund Management LLC now owns 353,292 shares of the biopharmaceutical company’s stock valued at $238,000 after acquiring an additional 34,473 shares during the period. Finally, Two Sigma Investments LP increased its position in shares of Sangamo Therapeutics by 182.7% in the third quarter. Two Sigma Investments LP now owns 2,479,186 shares of the biopharmaceutical company’s stock valued at $1,669,000 after acquiring an additional 1,602,107 shares during the period. Hedge funds and other institutional investors own 56.92% of the company’s stock.

Sangamo Therapeutics Price Performance

Shares of NASDAQ:SGMO opened at $0.14 on Monday. The stock has a market cap of $55.93 million, a PE ratio of -0.31 and a beta of 1.04. The company’s fifty day moving average is $0.27 and its 200 day moving average is $0.38. Sangamo Therapeutics has a 52 week low of $0.10 and a 52 week high of $0.77.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc is a clinical-stage biotechnology company headquartered in Brisbane, California, that specializes in the development of genomic therapies based on its proprietary zinc finger nuclease (ZFN) technology. Founded in 1995, Sangamo pioneered ZFN-based genome editing to precisely alter DNA sequences for the treatment of serious genetic and rare diseases. The company’s platform encompasses in vivo genome editing, ex vivo cell therapy, and genome regulation approaches, with a focus on durable therapeutic effects through permanent genetic modification or sustained gene expression control.

Through its genome editing programs, Sangamo is advancing multiple product candidates into clinical trials for conditions such as hemophilia A and B, mucopolysaccharidosis types I and II, and lysosomal storage disorders.